Small. Smart. Diabetes made easier.†

For people with type 1 diabetes.

Our latest insulin pump system with a small, sleek design that you can fully control from a phone.‡

MiniMed Flex system

Get more time in range now with a pump nearly half the width of a smartphone‡§

Automatically adjusts insulin delivery, and corrects highs every 5 minutes◊, 24/7.¶#

Real world results show T1D individuals achieved 80% Time in Range.◊Δ1

Real-world users spent on average 91% Time in Range during the night.Δ∞2

kid holding minimed flex pump into her pocket kid holding minimed flex pump into her pocket

“The pump is much lighter than what I was using before, and being able to manage everything from my phone means I hardly ever interact with the pump itself. Getting started was easy, intuitive, and stress free. ” §§

MiniMed Flex user.

Want to learn more about the MiniMedTM Flex system?

Leave your details and we will contact you to answer all your questions.

indicates a required field.

What type of diabetes do you have?

This field is required.

Sorry, Our pump therapy is approved for type 1 diabetes. Please contact your HCP if you have type 2 diabetes.

This field is required.
This field is required.
This field is required.
This field is required.
This field is required.
This field is required.
*
This field is required.

This form is for only United Kingdom

*
This field is required.

Are you currently using a Medtronic diabetes therapy?

This field is required.
This field is required.
This field is required.

For more information on how MiniMed handles your personal (health) data and your rights as a data subject – follow the link to MiniMed’s Privacy Statement. You can withdraw your consent at any time by accessing your profile account on the website and contacting your local MiniMed team.

I understand that the information provided is not intended to be a substitute for professional medical advice, diagnosis or treatment in any manner and that I should also contact my diabetes care team at my hospital or clinic for further advice relating to my individual circumstances.

We have received your submission. Thank you!

One of our Therapy Consultants will reach out to you within the next 48 working hours. 

Information contained herein is not medical advice and should not be used as an alternative to speaking with your healthcare team. Discuss indications, contraindications, warnings, precautions, potential adverse events and any further information with your healthcare professional. Please consult your healthcare professional for a full list of benefits, indications, precautions, clinical results and other important medical information that pertains to the therapy or products discussed. See the device manuals for detailed information regarding the instructions for use, indications, contraindications, warnings, precautions and potential adverse events. For further information, contact your local MiniMed representative.

 

Footnotes

† Compared to MDI.

‡ Compatible smartphone, pairing, connectivity, and settings required; some manual logging may also be needed. Incorrect dosing and serious injury can occur without proper setup. See user guide for full details.

§ Individual results may vary.

◊ Refers to SmartGuard™ feature. Individual results may vary.

¶ Optimal settings in adults: SmartGuard™ Target: 5.5 mmol/L, 2 hr AIT, ages <=15: Start at SmartGuard™ Target: 6.1 mmol/L and reduce to 5.5 mmol/L if no hypos, 2 hr AIT.

# Minimal adjustments to consider per visit (glucose target, AIT, insulin to carb ratio, and manual mode). Study data from Guardian 4 sensor and/or Simplera Sync sensor.

Δ In users >15 years old, using the optimal settings that are the combination of glucose target at 100 mg/dL (5.5 mmol/L) and Active Insulin Time (AIT) at 2 hours for at least 95% of the time. SmartGuard™ feature settings for each single patient must be defined by HCPs based on individual targets and specific needs.

∞ Due to inherent real-world study limitations, caution is advised when attempting to extrapolate these results to new patients. There could be significant differences. Overnight period: 12:00 AM–6:00 AM [24:00 h–06:00 h]. Number of users with ≥10 days of sensor glucose data; Optimal settings are glucose target at 5.5 mmol/L and Active Insulin Time (AIT) at 2 hours and used >95% of the time.

†† Taking a bolus 15 – 20 minutes before a meal helps to keep blood sugar levels under control after eating.

‡‡ Refer to User Guide.

§§ This person with diabetes testimonial relates an account of an individual’s response to the treatment. The account is genuine, typical and documented. However, the individual’s response does not provide any indication, guide, warranty or guarantee as to the response other patients may have to the treatment. The response other patients have to the treatment could be different. Responses to the treatment discussed can and do vary and are specific to the individual patient.

◊◊ Compared to standalone CGM therapy.

 

References

1. Arrieta A, et al. Diabetes Obes Metab. 2022;10.1111/dom.14714.

2. McVean J. et al Diabetes Obes Metab. 2026;28(3):2456-2460.

3. Petrovski G. et al. Diabetes Technol Ther. 2024;26(S3):76-83.

4. Grassi BA. Et al. Diabetes Technol Ther. 2026;28(4):374-380.

 

CE-DBA-2600398

DreaMed Diabetes is a trademark of DreaMed Diabetes, Ltd. The MiniMed™ Flex system algorithm includes technology developed by DreaMed Diabetes.